Immunic (NASDAQ:IMUX) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report issued on Monday.

Several other research firms have also commented on IMUX. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. Leerink Partners restated an “outperform” rating and issued a $5.00 price target on shares of Immunic in a research note on Monday, September 9th. B. Riley assumed coverage on Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 target price on the stock. Piper Sandler restated an “overweight” rating and set a $28.00 price target on shares of Immunic in a report on Tuesday, July 16th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Immunic presently has a consensus rating of “Buy” and an average target price of $11.20.

Immunic Trading Up 4.2 %

Shares of Immunic stock opened at $1.23 on Monday. Immunic has a 12 month low of $0.95 and a 12 month high of $2.11. The firm has a market capitalization of $110.80 million, a P/E ratio of -1.00 and a beta of 1.88. The business has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $1.35.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BVF Inc. IL bought a new stake in shares of Immunic in the first quarter worth approximately $11,752,000. Janus Henderson Group PLC bought a new stake in Immunic in the 1st quarter worth approximately $9,266,000. Vanguard Group Inc. grew its position in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the period. Ikarian Capital LLC raised its stake in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.